Skip to content

Study · Not a test of the peptide alone · 2006

2 results

Enhanced response of granulosa and theca cells from sheep carriers of the FecB mutation in vitro to gonadotropins and bone morphogenic protein-2, -4, and -6.

Campbell BK, Souza CJ, Skinner AJ, Webb R, Baird DT

Endocrinology5 Jan 2006Cited by 43 (Europe PMC)

PMID16396991 (opens in a new tab)DOI10.1210/en.2005-0604 (opens in a new tab)PepBankPUB-16396991
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Mechanism

    In sheep granulosa cells cultured with FSH, BMPs stimulated estradiol production with a clear interaction with IGF-I (LR3 analog).

    In plain wordsIn cells from sheep, BMPs raised estradiol production and this effect interacted with IGF-I. The study tested BMPs, not IGF-I alone.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableInteraction of BMPs with IGF-I on estradiol production by granulosa cells
    Study

    sheepn: not reported in source

    Cultured granulosa and theca cells
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    Dose-finding studies using ovaries from wild-type sheep obtained from the abbattoir showed no difference among the different BMPs in stimulating (P < 0.001) estradiol (E2) production by GCs cultured with FSH (10 ng/ml), but there was a clear interaction (P < 0.001) with IGF-I.
    1 context sentence
    Summary · context
    Experiments examined the effect of BMP-2, -4, and -6 (0.005-50 ng/ml), and their interaction with IGF-I (0.1-10 ng/ml LR3 analog) and gonadotropins, on the proliferation and differentiation of GCs and TCs isolated from small (<2 mm) antral follicles and maintained in serum-free culture for up to 8 d.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

  2. 02LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Mechanism

    With 0.1 ng/ml IGF-I, granulosa cells from FecB mutation ewes reached maximum estradiol and inhibin A production at BMP doses 3- to 10-fold lower than cells from non-carrier ewes.

    In plain wordsIn cells from sheep with the FecB mutation, lower BMP doses gave top hormone output than in cells without it, when IGF-I was low.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableBMP dose for maximum estradiol and inhibin A production at low IGF-I
    Study

    sheepn: not reported in source

    Cultured granulosa and theca cells
    Comparator
    Fec(+/+) ewes
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    In the presence of low concentrations of IGF-I (0.1 ng/ml), the maximum increase in the production of E2 and inhibin A by GCs from FF ewes in response to BMPs was observed at doses that were 3- to 10-fold lower (3-10 ng/ml) than ++ (30 ng/ml; P < 0.001).
    1 context sentence
    Summary · context
    Experiments examined the effect of BMP-2, -4, and -6 (0.005-50 ng/ml), and their interaction with IGF-I (0.1-10 ng/ml LR3 analog) and gonadotropins, on the proliferation and differentiation of GCs and TCs isolated from small (<2 mm) antral follicles and maintained in serum-free culture for up to 8 d.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.